Literature DB >> 19074424

The roles of selected arginine and lysine residues of TAFI (Pro-CPU) in its activation to TAFIa by the thrombin-thrombomodulin complex.

Chengliang Wu1, Paul Y Kim, Reg Manuel, Marian Seto, Marc Whitlow, Mariko Nagashima, John Morser, Ann Gils, Paul Declerck, Michael E Nesheim.   

Abstract

Thrombomodulin (TM) increases the catalytic efficiency of thrombin (IIa)-mediated activation of thrombin-activable fibrinolysis inhibitor (TAFI) 1250-fold. Negatively charged residues of the C-loop of TM-EGF-like domain 3 are required for TAFI activation. Molecular models suggested several positively charged residues of TAFI with which the C-loop residues could interact. Seven TAFI mutants were constructed to determine if these residues are required for efficient TAFI activation. TAFI wild-type or mutants were activated in the presence or absence of TM and the kinetic parameters of TAFI activation were determined. When the three consecutive lysine residues in the activation peptide of TAFI were substituted with alanine (K42/43/44A), the catalytic efficiencies for TAFI activation with TM decreased 8-fold. When other positively charged surface residues of TAFI (Lys-133, Lys-211, Lys-212, Arg-220, Lys-240, or Arg-275) were mutated to alanine, the catalytic efficiencies for TAFI activation with TM decreased by 1.7-2.7-fold. All decreases were highly statistically significant. In the absence of TM, catalytic efficiencies ranged from 2.8-fold lower to 1.24-fold higher than wild-type. None of these, except the 2.8-fold lower value, was statistically significant. The average half-life of the TAFIa mutants was 8.1+/-0.6 min, and that of wild type was 8.4+/-0.3 min at 37 degrees C. Our data show that these residues are important in the activation of TAFI by IIa, especially in the presence of TM. Whether the mutated residues promote a TAFI-TM or TAFI-IIa interaction remains to be determined. In addition, these residues do not influence spontaneous inactivation of TAFIa.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19074424      PMCID: PMC2652281          DOI: 10.1074/jbc.M804745200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  42 in total

1.  The molecular weights, mass distribution, chain composition, and structure of soluble fibrin degradation products released from a fibrin clot perfused with plasmin.

Authors:  J B Walker; M E Nesheim
Journal:  J Biol Chem       Date:  1999-02-19       Impact factor: 5.157

2.  Activation of thrombin-activable fibrinolysis inhibitor requires epidermal growth factor-like domain 3 of thrombomodulin and is inhibited competitively by protein C.

Authors:  K Kokame; X Zheng; J E Sadler
Journal:  J Biol Chem       Date:  1998-05-15       Impact factor: 5.157

3.  Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties.

Authors:  M B Boffa; W Wang; L Bajzar; M E Nesheim
Journal:  J Biol Chem       Date:  1998-01-23       Impact factor: 5.157

4.  Thrombin interacts with thrombomodulin, protein C, and thrombin-activatable fibrinolysis inhibitor via specific and distinct domains.

Authors:  S W Hall; M Nagashima; L Zhao; J Morser; L L Leung
Journal:  J Biol Chem       Date:  1999-09-03       Impact factor: 5.157

5.  TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex.

Authors:  L Bajzar; J Morser; M Nesheim
Journal:  J Biol Chem       Date:  1996-07-12       Impact factor: 5.157

6.  The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent.

Authors:  L Bajzar; M E Nesheim; P B Tracy
Journal:  Blood       Date:  1996-09-15       Impact factor: 22.113

7.  Activation and characterization of procarboxypeptidase B from human plasma.

Authors:  A K Tan; D L Eaton
Journal:  Biochemistry       Date:  1995-05-02       Impact factor: 3.162

8.  A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor.

Authors:  W Wang; M B Boffa; L Bajzar; J B Walker; M E Nesheim
Journal:  J Biol Chem       Date:  1998-10-16       Impact factor: 5.157

9.  Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor.

Authors:  L Bajzar; R Manuel; M E Nesheim
Journal:  J Biol Chem       Date:  1995-06-16       Impact factor: 5.157

10.  The three-dimensional structure of the native ternary complex of bovine pancreatic procarboxypeptidase A with proproteinase E and chymotrypsinogen C.

Authors:  F X Gomis-Rüth; M Gómez; W Bode; R Huber; F X Avilés
Journal:  EMBO J       Date:  1995-09-15       Impact factor: 11.598

View more
  7 in total

Review 1.  Thrombomodulin and its role in inflammation.

Authors:  Edward M Conway
Journal:  Semin Immunopathol       Date:  2011-07-31       Impact factor: 9.623

2.  Solulin increases clot stability in whole blood from humans and dogs with hemophilia.

Authors:  Jonathan H Foley; Karl-Uwe Petersen; Catherine J Rea; Lori Harpell; Sandra Powell; David Lillicrap; Michael E Nesheim; Benny Sørensen
Journal:  Blood       Date:  2012-01-10       Impact factor: 22.113

3.  Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates fibrin-dependent plasmin generation on thrombin-activated platelets.

Authors:  Ran Ni; Miguel A D Neves; Chengliang Wu; Samantha E Cerroni; Matthew J Flick; Heyu Ni; Jeffrey I Weitz; Peter L Gross; Paul Y Kim
Journal:  J Thromb Haemost       Date:  2020-09       Impact factor: 5.824

4.  Thrombomodulin: a bifunctional modulator of inflammation and coagulation in sepsis.

Authors:  Takayuki Okamoto; Hironobu Tanigami; Koji Suzuki; Motomu Shimaoka
Journal:  Crit Care Res Pract       Date:  2012-02-28

5.  Identification and characterization of a factor Va-binding site on human prothrombin fragment 2.

Authors:  Alexander P Friedmann; Anatoli Koutychenko; Chengliang Wu; James C Fredenburgh; Jeffrey I Weitz; Peter L Gross; Ping Xu; Feng Ni; Paul Y Kim
Journal:  Sci Rep       Date:  2019-02-21       Impact factor: 4.379

Review 6.  Thrombin Activatable Fibrinolysis Inhibitor (TAFI): An Updated Narrative Review.

Authors:  Machteld Sillen; Paul J Declerck
Journal:  Int J Mol Sci       Date:  2021-04-01       Impact factor: 5.923

Review 7.  Coagulation Dysfunction in Acute Respiratory Distress Syndrome and Its Potential Impact in Inflammatory Subphenotypes.

Authors:  Samantha A Livingstone; Karin S Wildi; Heidi J Dalton; Asad Usman; Katrina K Ki; Margaret R Passmore; Gianluigi Li Bassi; Jacky Y Suen; John F Fraser
Journal:  Front Med (Lausanne)       Date:  2021-08-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.